Targeting Mycobacterium tuberculosis CoaBC through Chemical Inhibition of 4′-Phosphopantothenoyl-<scp>l</scp>-cysteine Synthetase (CoaB) Activity

Joanna C. Evans, Dinakaran Murugesan, John Post, V. Mendes, Zhe Wang, Navid Nahiyaan, Sasha Lynch, Stephen Thompson, Simon R. Green, Peter C. Ray, Jeannine Hess, Christina Spry, Anthony G. Coyne, Chris Abell, Helena I. Boshoff, Paul G. Wyatt, Kyu Y. Rhee, Tom L. Blundell, Clifton E. Barry, Valerie MizrahiACS 2021 · DOI

TL;DR

Researchers have identified a novel small molecule, compound 1f, that specifically inhibits the CoaB enzyme in Mycobacterium tuberculosis (Mtb), the bacterium responsible for tuberculosis. This discovery is significant because it validates CoaBC, a key enzyme in the essential Coenzyme A (CoA) biosynthesis pathway, as a promising drug target and demonstrates that it's possible to develop compounds with whole-cell activity against Mtb.

What Problem Does This Paper Address?

Tuberculosis (TB) remains a major global health threat, exacerbated by the rise of drug-resistant strains. Developing new antitubercular agents with novel mechanisms of action is crucial. The Coenzyme A (CoA) biosynthesis pathway is an attractive target because CoA is vital for numerous cellular processes, and the bacterial pathway differs from its human counterpart, offering selectivity. While previous work had genetically validated the CoaBC enzyme as a potential target, finding potent and selective small molecule inhibitors with actual whole-cell activity against Mtb had been a significant challenge. Many promising biochemical inhibitors failed to translate into effective drugs due to issues like poor cell penetration, efflux, or rapid metabolism within the bacteria.

Methods

The study employed a multi-pronged approach:

  • High-Throughput Screening (HTS): A library of over 200,000 small molecules was screened to identify initial inhibitors of Mtb CoaB.
  • Structure-Activity Relationship (SAR) Studies: Based on initial hits, a series of analogues were synthesized and tested to understand how chemical modifications affected enzyme inhibition and whole-cell activity.
  • Biochemical Assays: Enzyme kinetics (IC50, Km, inhibition type) were determined using a coupled enzyme assay and differential scanning fluorimetry (DSF) to understand how inhibitors interact with the enzyme and its substrates.
  • Whole-Cell Assays: Minimum inhibitory concentrations (MICs) were determined against replicating Mtb.
  • Hypomorph Screening: A conditional knockdown mutant (hypomorph) of CoaBC was used to assess target selectivity. If a compound's potency increases when the target gene's expression is reduced, it strongly suggests on-target activity.
  • Bypass Assays: Supplementing the growth medium with pantethine (PantS) was used to bypass the CoaBC enzyme. If the compound's toxicity is reduced by PantS, it further supports CoaBC as the target.
  • Metabolomic Profiling: Changes in intracellular metabolite levels were analyzed using LC-MS to understand the biochemical consequences of compound exposure and confirm pathway disruption.
  • Compound Uptake Studies: The intracellular accumulation of compounds was measured to assess their ability to enter Mtb.

Datasets

The study utilized a library of 215,000 small molecules from the DDU compound collection for the initial high-throughput screening. No new benchmark datasets were introduced.

Key Insights and Ideas

  • CoaBC is indeed druggable: The identification of compound 1f with demonstrated whole-cell activity and target engagement provides strong evidence that CoaBC can be effectively targeted for therapeutic intervention.
  • Whole-cell activity is the bottleneck: The study highlights that even potent biochemical inhibitors may fail if they cannot effectively reach or persist within the bacterial cell. This underscores the importance of considering pharmacokinetic and pharmacodynamic properties early in drug discovery.
  • Hypomorphs are powerful tools: Using a coaBC hypomorph was critical in confirming that compound 1f's activity was indeed linked to CoaBC, as the compound became significantly more potent when CoaBC expression was reduced.
  • Metabolomics provides a window into pathway disruption: The observed metabolic signature (accumulation of dephospho-CoA, depletion of acyl-CoAs) strongly correlated with CoaBC inhibition and provided mechanistic insight.
  • Uncompetitive inhibition is a distinct mechanism: Compound 1f's uncompetitive inhibition with respect to 4'-phosphopantothenate (PPA) is a key finding, suggesting a binding mode that differs from previously identified allosteric inhibitors and offering new avenues for inhibitor design.

Key Results

  • Compound 1f was identified as a direct inhibitor of Mtb CoaB with an IC50 of 15.6 µM.
  • 1f showed modest whole-cell activity against Mtb with a Minimum Inhibitory Concentration (MIC) of 25.9 µM.
  • In a coaBC hypomorph strain, the MIC of 1f was reduced by approximately 7-fold in the presence of anhydrotetracycline (ATc), indicating on-target activity.
  • Supplementation with pantethine (PantS) rescued Mtb from 1f toxicity, further supporting CoaBC as the target.
  • Metabolomic analysis of Mtb treated with 1f revealed significant accumulation of dephospho-CoA and depletion of propionyl-CoA, succinyl-CoA, and malonyl-CoA, consistent with CoA pathway disruption.
  • Compound 1f was found to inhibit CoaBC uncompetitively with respect to PPA, and noncompetitively with respect to CTP and L-cysteine.
  • While 1f showed similar IC50 values against Mtb CoaB and human CoaB (HCoaB), its whole-cell activity and hypomorph data suggest sufficient selectivity for Mtb.

Limitations and Future Work

  • Selectivity: Compound 1f showed similar IC50 values against Mtb CoaB and human CoaB, indicating a lack of selectivity. Future work will focus on exploiting other chemical properties to achieve better selectivity.
  • Metabolic Complexity: The precise mechanisms underlying the observed metabolic changes, particularly the depletion of ATP and its potential role in dephospho-CoA accumulation, are complex and not fully understood. Further investigation into the intricate regulatory mechanisms of CoA biosynthesis in Mtb is warranted.
  • Drug Development: While 1f represents a significant advance, it is described as a "lead compound." Further optimization will be necessary to improve potency, selectivity, and pharmacokinetic properties for potential therapeutic development. The authors are actively pursuing these efforts.

Summary updated

Abstract

Coenzyme A (CoA) is a ubiquitous cofactor present in all living cells and estimated to be required for up to 9% of intracellular enzymatic reactions. <i>Mycobacterium tuberculosis</i> (Mtb) relies on its own ability to biosynthesize CoA to meet the needs of the myriad enzymatic reactions that depend on this cofactor for activity. As such, the pathway to CoA biosynthesis is recognized as a potential source of novel tuberculosis drug targets. In prior work, we genetically validated CoaBC as a bactericidal drug target in Mtb <i>in vitro</i> and <i>in vivo</i>. Here, we describe the identification of compound <b>1f</b>, a small molecule inhibitor of the 4'-phosphopantothenoyl-l-cysteine synthetase (PPCS; CoaB) domain of the bifunctional Mtb CoaBC, and show that this compound displays on-target activity in Mtb. Compound <b>1f</b> was found to inhibit CoaBC uncompetitively with respect to 4'-phosphopantothenate, the substrate for the CoaB-catalyzed reaction. Furthermore, metabolomic profiling of wild-type Mtb H37Rv following exposure to compound <b>1f</b> produced a signature consistent with perturbations in pantothenate and CoA biosynthesis. As the first report of a direct small molecule inhibitor of Mtb CoaBC displaying target-selective whole-cell activity, this study confirms the druggability of CoaBC and chemically validates this target.
BibTeX
@inproceedings{evans2021targeting,
  author = {Joanna C. Evans and Dinakaran Murugesan and John Post and V. Mendes and Zhe Wang and Navid Nahiyaan and Sasha Lynch and Stephen Thompson and Simon R. Green and Peter C. Ray and Jeannine Hess and Christina Spry and Anthony G. Coyne and Chris Abell and Helena I. Boshoff and Paul G. Wyatt and Kyu Y. Rhee and Tom L. Blundell and Clifton E. Barry and Valerie Mizrahi},
  title = {{Targeting <i>Mycobacterium tuberculosis</i> CoaBC through Chemical Inhibition of 4′-Phosphopantothenoyl-<scp>l</scp>-cysteine Synthetase (CoaB) Activity}},
  booktitle = {ACS},
  year = {2021},
  doi = {10.1021/acsinfecdis.0c00904},
}
Figure